How to Apply for the Gaudium IVF and Women Health IPO: Step-by-Step Investment Guide

Summary:


Gaudium IVF and Women Health Limited has launched its book-building IPO, scheduled to open from February 20 to February 24, 2026, with listing proposed on BSE and NSE on February 27, 2026. The issue is priced in the band of ₹75 to ₹79 per share with a face value of ₹5 per share and a lot size of 189 shares. The total issue size comprises 2,08,86,200 equity shares aggregating up to ₹165 crore, including a fresh issue of 1,13,92,500 shares (up to ₹90 crore) and an offer for sale of 94,93,700 shares (up to ₹75 crore). The public offering is structured as a combination of fresh capital and offer for sale under the book-building route.

Gaudium IVF and Women Health Limited operates in the assisted reproductive technology and women’s healthcare segment, providing IVF and related fertility treatments across multiple centres in India. Investors can apply for the IPO through the ASBA (Application Supported by Blocked Amount) facility available via their bank’s net-banking portal. Applicants need to select the Gaudium IVF and Women Health Limited IPO from the list of active issues, enter the bid quantity and price within the specified range, and authorise the blocking of funds in their bank account. The blocked amount remains in the account until the allotment process is completed. Upon finalisation of allotment, shares, if allotted, are credited to the investor’s demat account and the corresponding amount is debited, while any unallotted portion is released.

Applications can also be submitted through the UPI mechanism using a supported trading or investment platform. After placing the bid, investors receive a mandate request on their UPI application, which must be approved within the stipulated timeline to validate the application. Funds remain blocked until the allotment status is determined, following which the release or adjustment of funds takes place in accordance with the IPO process.

For more details, visit the Gaudium IVF and Women Health Limited IPO page.

Gaudium IVF and Women Health Limited IPO Details and Objectives

Details

Information

IPO Date

Feb 20, 2026 to Feb 24, 2026

Issue Size

2,08,86,200 shares (agg. up to ₹165 Cr)

Price Band

₹75 to ₹79 per share

Lot Size

189 Shares

Listing At

BSE, NSE

Purpose of the IPO

  • Funding capital expenditure towards establishment of New IVF Centers of the Company

  • Repayment/pre-payment, in full or in part, of certain outstanding loans availed by the Company

  • General Corporate Expenses

Timeline of Gaudium IVF and Women Health Limited IPO

Event

Date

IPO Open Date

Fri, Feb 20, 2026

IPO Close Date

Tue, Feb 24, 2026

Tentative Allotment

Wed, Feb 25, 2026

Initiation of Refunds

Wed, Feb 25, 2026

Credit of Shares to Demat

Thu, Feb 26, 2026

Tentative Listing Date

Fri, Feb 27, 2026

Cut-off time for UPI mandate confirmation

5 PM on Tue, Feb 24, 2026

Pricing & Lot Size of Gaudium IVF and Women Health Limited IPO

Price Band for the IPO

  • ₹75 to ₹79 per share

Minimum Lot Size and Application Details

Application

Lots

Shares

Amount

Individual investors (Retail) (Min)

1

189

₹14,931

Individual investors (Retail) (Max)

13

2,457

₹1,94,103

S-HNI (Min)

14

2,646

₹2,09,034

S-HNI (Max)

66

12,474

₹9,85,446

B-HNI (Min)

67

12,663

₹10,00,377

Gaudium IVF and Women Health Limited IPO Application Process

The Gaudium IVF and Women Health Limited IPO application process can be completed online through your trading platform. Below is a step-by-step guide to applying for the IPO:

Step 1: Login to Your Trading Platform

Access your trading account using the broker's app or website.

Step 2: Navigate to the IPO Section

Go to the IPO section to view active IPO listings.

Step 3: Select the Open IPO and Click Apply

Locate Gaudium IVF and Women Health Limited IPO in the list of available IPOs and click the ‘Apply’ button.

Step 4: Enter the Quantity of Shares You Wish to Apply For

Specify the number of shares (lot size: 189 shares) within the price band of ₹75 to ₹79 per share.

Step 5: Provide Your UPI ID

Enter your UPI ID for payment authorisation and ensure sufficient funds in your bank account.

Step 6: Confirm the Application

Review your application details and confirm the UPI mandate before 5 PM on the last application day.

Step 7: Complete the Process and Wait for Allotment

Submit the application and monitor the allotment status to check if shares have been allocated to you.

Shares Offered in Gaudium IVF and Women Health IPO

The allocation of shares in the Gaudium IVF and Women Health IPO is structured in accordance with the book-building regulations applicable to mainboard public issues. The reservation framework specifies the proportion of the net issue available to Qualified Institutional Buyers (QIBs), Non-Institutional Investors (NIIs), and Retail Individual Investors (RIIs). The distribution is expressed as a percentage of the net issue and outlines the minimum and maximum allocation thresholds for each category.

Investor Category

Shares Offered

QIB Shares Offered

Not more than 50.00% of the Net Issue

Retail Shares Offered

Not less than 35.00% of the Net Issue

NII Shares Offered

Not less than 15.00% of the Net Issue

This structure reflects the reservation norms disclosed for the issue and indicates the proportion of shares available to each investor segment under the book-building process.

Financial Health and Performance

Key Financial Metrics

  • Total Assets: Increased from ₹36.63 crore in FY23 to ₹106.62 crore as of Sept 2025.

  • Total Income: Recorded at ₹49.75 crore in Sept 2025, as compared to ₹44.26 crore in FY23.

  • Profit After Tax (PAT): Reported at ₹12.51 crore in Sept 2025, and ₹13.53 crore in FY23.

  • Net Worth: Recorded at ₹58.85 crore in Sept 2025 in comparison to ₹22.73 crore in FY23.

  • Reserves and Surplus: Stood at ₹28.16 crore in Sept 2025, as compared to ₹21.74 crore in FY23.

  • EBITDA: Stood at ₹18.95 crore in Sept 2025 in comparison to ₹20.07 crore in FY23.

Recent Performance and Growth Prospects

  • The company’s asset base has expanded over the review period, reflecting scaling of operations and alignment of resources with business requirements.

  • Income levels have shown movement across reporting periods, indicating operational activity and participation within its service segment.

  • Profitability has remained positive across the reviewed periods, reflecting sustained earnings generation.

  • The net worth position has strengthened over time, supported by retained earnings and overall balance sheet growth.

  • Reserves have increased over the review period, contributing to the company’s capital base and financial stability.

  • Operating performance, as reflected in earnings before interest, tax, depreciation and amortisation, indicates continued operating-level performance across reporting periods.

  • Overall financial movement suggests progression in operational scale and strengthening of the balance sheet during the review period.

Investment Risks and Opportunities

Potential Risks of Investing in the IPO

  • The company operates in the assisted reproductive technology (ART) and fertility treatment segment, where performance may be influenced by regulatory developments, clinical compliance requirements, and evolving healthcare standards.

  • Demand for IVF and related fertility procedures can be affected by economic conditions, treatment affordability, and changing patient preferences, which may influence revenue visibility.

  • The business is dependent on medical professionals, embryologists, and specialised healthcare staff. Any challenges in retaining skilled personnel could impact service delivery and operational continuity.

  • Expansion across multiple centres requires consistent quality control and infrastructure management, and variations in centre-level performance may affect overall operating outcomes.

Opportunities and Growth Potential

  • Rising awareness of assisted reproductive technology, delayed parenthood trends, and increasing maternal age support long-term demand growth in the IVF segment.

  • Expansion through a hub-and-spoke model enables wider geographic reach while centralising specialised capabilities, potentially supporting scalability.

  • Growing acceptance of fertility treatments among domestic and international patients may contribute to patient inflow across centres.

  • Advancements in reproductive technology and broader healthcare access may strengthen the company’s participation within the evolving fertility care ecosystem.

Key Performance Indicator (KPI)

KPI

Sept 30, 2025

Mar 31, 2025

ROE

21.25%

41.31%

ROCE

21.03%

39.70%

Debt/Equity

0.38

0.41

RoNW

21.34%

41.71%

PAT Margin

25.14%

26.96%

EBITDA Margin

38.29%

40.48%

Price to Book Value

10.48

Gaudium IVF and Women Health Limited IPO Registrar & Lead Managers

Registrar

Lead Manager(s)

Bigshare Services Pvt.Ltd.

Sarthi Capital Advisors Pvt.Ltd.

Company Address of Gaudium IVF and Women Health Limited

Gaudium IVF & Women Health Ltd.

B1/51, Janak Puri,

B-1, New Delhi, New Delhi, 110058

Phone: 011-4885 8585

Email: compliance@gaudiumivfcentre.com

Website: https://www.gaudiumivfcentre.com/

Interested in more opportunities? Check out our Upcoming IPO section for new listings and don’t forget to check your Gaudium IVF and Women Health IPO allotment status.

Frequently Asked Questions

No result found

search icon
Published Date : 19 Feb 2026

Disclaimer :

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.


The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.



Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited



This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing. 

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Read More Blogs

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

11 lakh+ Users

icon-with-text

4.8 App Rating

icon-with-text

4 Languages

icon-with-text

₹7,900+ Cr MTF Book

icon-with-text
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|